10 results on '"García, Marco J."'
Search Results
2. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
- Author
-
González-Barca, E., Canales, M., Salar, A., Ferreiro-Martínez, J., Ferrer-Bordes, S., García-Marco, J., Sánchez-Blanco, J., García-Frade, J., Peñalver, J., Bello-López, J., Sancho, J., Caballero, D., González-Barca, E, Ferreiro-Martínez, J J, García-Marco, J A, Sánchez-Blanco, J J, García-Frade, J, Peñalver, J, Bello-López, J L, and Sancho, J M
- Subjects
- *
CENTRAL nervous system diseases , *PREVENTIVE medicine , *CYTARABINE , *B cell lymphoma , *DIFFUSE large B-cell lymphomas , *CLINICAL trials , *PREVENTION , *ANTIMETABOLITES , *ANTINEOPLASTIC agents , *COMPARATIVE studies , *DOXORUBICIN , *SPINAL injections , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *MONOCLONAL antibodies , *PREDNISONE , *RESEARCH , *SURVIVAL , *VINCRISTINE , *EVALUATION research , *CYCLOPHOSPHAMIDE , *DIAGNOSIS - Abstract
The dissemination in the central nervous system (CNS) is an uncommon but fatal complication occurring in patients with diffuse large B-cell lymphoma (DLBCL). Standard prophylaxis has been demonstrated to reduce CNS relapse and improve survival rates. Intrathecal (IT) liposomal cytarabine allows maintaining elevated drug levels in the cerebrospinal fluid for an extended period of time. Data on the efficacy and safety of liposomal cytarabine as CNS prophylaxis in patients with DLBCL are still insufficient. The objective of the present study was to evaluate the effectiveness and safety of the prophylaxis with IT liposomal cytarabine in prevention of CNS relapse in high-risk patients with DLBCL who were included in a trial of first line systemic therapy with 6 cycles of dose-dense R-CHOP every 14 days. Twenty-four (18.6 %) out of 129 patients were identified to have risk factors for CNS involvement, defined as follows: >30 % bone marrow infiltration, testes infiltration, retroperitoneal mass ≥10 cm, Waldeyer ring, or bulky cervical nodes involvement. Liposomal cytarabine (50 mg) was administered by lumbar puncture the first day of the 1st, 2nd, and 6th cycle of R-CHOP14 scheme. Among 70 IT infusions, grade 3-4 adverse events reported were headache (one patient) and nausea/vomiting (one patient). With a median follow-up of 40.1 months, no CNS involvement by DLBCL was observed in any patient. In conclusion, IT liposomal cytarabine is safe, feasible, and effective for CNS prophylaxis, causing few associated risks and little discomfort to patients with DLBCL. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Growth differentiation factor 11 ( GDF11) - a promising anti-ageing factor - is highly concentrated in platelets.
- Author
-
Bueno, J. L., Ynigo, M., Miguel, C., Gonzalo‐Daganzo, R. M., Richart, A., Vilches, C., Regidor, C., García‐Marco, J. A., Flores‐Ballester, E., and Cabrera, J. R.
- Subjects
- *
MYOSTATIN , *BLOOD plasma , *BLOOD donors , *BLOOD platelets , *BLOOD proteins , *BLOOD transfusion - Abstract
Recent research suggests that growth differentiation factor 11 ( GDF11) could reverse age-related diseases and that its blood concentration decreases with age. This poses plasma from young donors as a therapeutic GDF11 source to treat age-related diseases. In addition, the tissue source of circulating GDF11 remains unknown. We analysed GDF11 levels in paired samples of serum, plasma and platelet lysate ( PL) from 23 volunteers. Plasma and PL were collected by plateletpheresis. Here, we show that GDF11 is highly concentrated in platelets and that the circulating levels reported in previous studies could be biased as a result of serum sample manipulation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. Immune reconstitution after cord blood transplants supported by coinfusion of mobilized hematopoietic stem cells from a third party donor.
- Author
-
Martín-Donaire, T., Rico, M., Bautista, G., Gonzalo-Daganzo, R., Regidor, C., Ojeda, E., Sanjuán, I., Forés, R., Ruiz, E., Krsnik, I., Navarro, B., Gil, S., Magro, E., Millán, I., Sánchez, R., Pérez-Sanz, N., Panadero, N., García-Marco, J. A., Cabrera, R., and Fernández, M. N.
- Subjects
- *
GRAFT versus host disease , *HEMATOPOIETIC stem cells , *GRANULOCYTES , *TRANSPLANTATION of organs, tissues, etc. , *SURGICAL excision - Abstract
Low severity of GVHD, substantial graft vs tumor (GVT) and slow development of protective immunity are well-documented features of cord blood transplants (CBT). We have evaluated the immune reconstitution of adult recipients of single-unit CBT supported by the coinfusion of third party donor (TPD) mobilized hematopoietic stem cells (MHSC), a procedure—‘dual CB/TPD-MHSC transplant’—that results in early recovery of circulating granulocytes, high rates of CB engraftment and full chimerism. Cumulative recovery of natural killer and B cells at or above the median values of normal controls were 1.0 and 0.76 by the sixth and ninth months. Recovery of T cells was much slower, naive cells lagging behind those of memory and effector (committed) immunophenotypes. Serial analyses of signal joint TCR excision circles showed a general pattern of very low levels by the third month after CBT, followed by recovery to levels persistently similar or higher than those observed before transplantation and in normal controls. Our results are consistent with the clinical observations of substantial GVT effect together with low incidence of serious GVHD and slow development of protective immunity and suggest that thymic function contributes substantially to the recovery of T-cell populations in adults receiving dual CB/TPD-MHSC transplants. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
5. Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor.
- Author
-
Bautista, G., Cabrera, J. R., Regidor, C., Forés, R., García-Marco, J. A., Ojeda, E., Sanjuán, I., Ruiz, E., Krsnik, I., Navarro, B., Gil, S., Magro, E., De Laiglesia, A., Gonzalo-Daganzo, R., Martín-Donaire, T., Rico, M., Millán, I., and Fernández, M. N.
- Subjects
- *
CORD blood transplantation , *HEMATOPOIETIC stem cells , *BLOOD diseases , *GRAFT versus host disease , *CLINICAL trials , *PATIENTS - Abstract
This open label clinical study provides updated evaluation of the strategy of single unit cord blood transplants (CBTs) with co-infusion of third-party donor (TPD) mobilized hematopoietic stem cells (MHSC). Fifty-five adults with high-risk hematological malignancies, median age 34 years (16–60 years) and weight 70 kg (43–95 kg), received CBTs (median 2.39 × 107 total nucleated cell (TNC) per kg and 0.11 × 106 CD34+ per kg) and TPD-MHSC (median 2.4 × 106 CD34+ per kg and 3.2 × 103 CD3+ per kg). Median time to ANC and to CB-ANC >0.5 × 109/l as well as to full CB-chimerism was 10, 21 and 44 days, with maximum cumulative incidences (MCI) of 0.96, 0.95 and 0.91. Median time to unsupported platelets >20 × 109/l was 32 days (MCI 0.78). MCI for grades I–IV and III–IV acute GVHD (aGVHD) were 0.62 and 0.11; 12 of 41 patients (29%) who are at risk developed chronic GVHD, becoming severely extensive in three patients. Relapses occurred in seven patients (MCI=0.17). The main causes of morbi-mortality were post-engraftment infections. CMV reactivations were the most frequent, their incidence declining after the fourth month. Five-year overall survival and disease-free survival (Kaplan–Meier) were 56 % and 47% (63% and 54% for patients 40 years). In conclusion, CBT with single units of relatively low cell content and 0–3 HLA mismatches is feasible as a first choice option for adult patients who lack a readily available adequate adult donor.Bone Marrow Transplantation (2009) 43, 365–373; doi:10.1038/bmt.2008.329; published online 13 October 2008 [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
6. Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation.
- Author
-
Rodríguez, A., Villuendas, R., Yáñez, L., Gómez, M. E., Díaz, R., Pollán, M., Hernández, N., de la Cueva, P., Marín, M. C., Swat, A., Ruiz, E., Cuadrado, M. A., Conde, E., Lombardía, L., Cifuentes, F., Gonzalez, M., García-Marco, J. A., and Piris, M. A.
- Subjects
- *
CHRONIC lymphocytic leukemia , *GENE expression , *IMMUNOGLOBULINS , *BLOOD proteins , *LYMPHOPROLIFERATIVE disorders - Abstract
Chronic lymphocytic leukemia (CLL), the most frequent form of adult leukemia in Western countries, is characterized by a highly variable clinical course. Expression profiling of a series of 160 CLL patients allowed interrogating the genes presumably playing a role in pathogenesis, relating the expression of functionally relevant signatures with the time to treatment. First, we identified genes relevant to the biology and prognosis of CLL to build a CLL disease-specific oligonucleotide microarray. Second, we hybridized a training series on the CLL-specific chip, generating a biology-based predictive model. Finally, this model was validated in a new CLL series. Clinical variability in CLL is related with the expression of two gene clusters, associated with B-cell receptor (BCR) signaling and mitogen-activated protein kinase (MAPK) activation, including nuclear factor-κB1 (NF-κB1). The expression of these clusters identifies three risk-score groups with treatment-free survival probabilities at 5 years of 83, 50 and 17%. This molecular predictor can be applied to early clinical stages of CLL. This signature is related to immunoglobulin variable region somatic hypermutation and surrogate markers. There is a molecular heterogeneity in CLL, dependent on the expression of genes defining BCR and MAPK/NF-κB clusters, which can be used to predict time to treatment in early clinical stages.Leukemia (2007) 21, 1984–1991; doi:10.1038/sj.leu.2404831; published online 5 July 2007 [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
7. AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-?B survival pathway.
- Author
-
Escobar-Díaz, E., López-Martín, E. M., Hernández del Cerro, M., Puig-Kroger, A., Soto-Cerrato, V., Montaner, B., Giralt, E., García-Marco, J. A., Pérez-Tomás, R., and Garcia-Pardo, A.
- Subjects
- *
SERRATIA marcescens , *CYCLIC peptides , *APOPTOSIS , *CANCER cells , *ANTINEOPLASTIC agents , *LEUKEMIA - Abstract
Clinical treatment of B-cell chronic lymphocytic leukemia (B-CLL) is limited by the progressive drug resistance and nonselectivity of most drugs towards malignant cells. Depsipeptides are present in certain bacteria and display potent antitumor activity. We have studied the effect of the novel cyclodepsipeptide AT514 (serratamolide) from Serratia marcescens on B-CLL cell viability. AT514 induced apoptosis of B-CLL cells from the 21 patients studied, as confirmed by Annexin-V binding and nuclei condensation, with an average IC50 of 13?µM. AT514 was effective in those B-CLL cases resistant to fludarabine, but had no effect on normal PBL. AT514 preferentially activated the intrinsic apoptotic pathway, as evidenced by loss of mitochondrial membrane potential, release of cytochrome c and activation of caspase-9 and -3, but not of caspase-8. Importantly, AT514 interfered with phosphatidylinositol-3 kinase and protein kinase C survival signals since it increased the apoptotic effect of LY294002 and BisI inhibitors, and induced Akt dephosphorylation at Ser 473. AT514 also decreased NF-?B activity by dramatically reducing the levels of p65 in B-CLL. This was confirmed on functional assays using NF-?B-luc-transfected Raji cells and transgenic mice. Our results establish that AT514 induces apoptosis of primary B-CLL cells and could be useful for clinical treatment of this malignancy.Leukemia (2005) 19, 572-579. doi:10.1038/sj.leu.2403679 Published online 3 March 2005 [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
8. A sustained activation of PI3K/NF-?B pathway is critical for the survival of chronic lymphocytic leukemia B cells.
- Author
-
Cuní, S., Pérez-Aciego, P., Pérez-Chacón, G., Vargas, J. A., Sánchez, A., Martín-Saavedra, F. M., Ballester, S., García-Marco, J., Jordá, J., and Dur´ntez, A.
- Subjects
- *
LYMPHOCYTIC leukemia , *B cells , *LYMPHOPROLIFERATIVE disorders , *NF-kappa B , *CELL proliferation , *LEUKEMIA - Abstract
The progressive rise of mature CD5+ B lymphocytes, despite the low proportion of proliferating cells, has led to the notion that B cell chronic lymphocytic leukemia (B-CLL) is primarily related to defective apoptosis. The microenvironment likely plays a prominent role because the malignant cells progressively accumulate in vivo, whereas they rapidly undergo spontaneous apoptosis when cultured in vitro. To assess microenvironment-mediated survival signals, B-CLL cells were cultured with a murine fibroblast cell line, Ltk-, with and without an agonistic antibody to CD40. Spontaneous apoptosis was associated with the loss of Akt and NF-?B activities. Interactions with fibroblasts sustained a basal level of Akt and NF-?B activities, which was dependent on phosphatidylinositol-3 kinase (PI3K). Constitutive activity of the PI3K pathway in B-CLL cells when cultured with fibroblasts prevented the downregulation of the prosurvival Bcl-2 family protein Bcl-xL and the caspase inhibitor proteins FLIPL and XIAP, and consequently caspase-3 activation and apoptosis. CD40 crosslinking in B-CLL cells did not further prevent murine fibroblasts-mediated apoptosis but induced cell proliferation, which was associated with an increase of Akt and NF-?B activation compared with cells cultured with fibroblasts alone. The PI3K pathway seems to play a pivotal role in B-CLL cell survival and growth.Leukemia (2004) 18, 1391-1400. doi:10.1038/sj.leu.2403398 Published online 3 June 2004 [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
9. Cord blood transplants: early recovery of neutrophils from co-transplanted sibling haploidentical progenitor cells and lack of engraftment of cultured cord blood cells, as ascertained by analysis of DNA polymorphisms.
- Author
-
Fernández, M N, Regidor, C, Cabrera, R, García-Marco, J, Briz, M, Forés, R, Sanjuán, I, McWhinnie, A, Querol, S, García, J, and Madrigal, A
- Subjects
- *
CORD blood , *NEUTROPHILS , *GENETIC polymorphisms , *TRANSPLANTATION of organs, tissues, etc. - Abstract
The number of infused cells is a very important factor in cord blood transplant (CBT) engraftment. Prior ex vivo expansion of aliquots of transplanted cord blood (CB) units is being investigated as a procedure to increase engraftment potential, but results are difficult to evaluate due to a lack of markers for assessing the contribution of expanded cells. We transplanted five patients, infusing the best available CB unit and cells from a second donor simultaneously. In two patients, these cells were obtained from another frozen CB unit by CD34+positive selection and culture expansion; the other three patients received uncultured highly purified haploidentical CD34+ cells. The first two patients had DNA from the culture expanded CB cells detected only for a few days around day +11 when the absolute neutrophil count (ANC) was >200/μl; thereafter and when the ANC was <500/μl, only donor DNA from the uncultured CB was detected. For the other three patients, DNA analysis showed early and transient granulocyte engraftment of haploidentical cells, progressively replaced by the CB-derived granulocytes. We concluded that: (1) simultaneous infusion of lymphocyte-depleted HLA highly mismatched haematopoietic progenitor cells has not produced unfavourable effects for CBT; (2) the double transplant model is suitable for evaluating the engraftment potential of ex vivocultured CB cells in the clinical setting; (3) the culture conditions used did not result in early recovery of ANC; and (4) co-transplantation of purified uncultured HLA haploidentical CD34+ cells may reduce the time of neutropenia following CBT.Bone Marrow Transplantation (2001) 28, 355–363. [ABSTRACT FROM AUTHOR]
- Published
- 2001
10. Chagas disease in a recipient of cord blood transplantation.
- Author
-
Forés, R., Sanjuán, I., Portero, F., Ruiz, E., Regidor, C., López-Vélez, R., Linares, M., Gil, S., Ojeda, E., Krsnik, I., Bautista, G., Vallejo, C., García-Marco, J., Fernández, M. N., and Cabrera, J. R.
- Subjects
- *
LETTERS to the editor , *CHAGAS' disease - Abstract
A letter to the editor discussing about the Chagas' disease in a recipient of cord blood transplantation is presented.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.